LOS ANGELES, California — Terray Therapeutics, an AI-native, chemistry-focused biotechnology company, announced that it has achieved a discovery milestone in its multi-target collaboration with Bristol Myers Squibb. The achievement highlights the strength of Terray’s proprietary AI platform, EMMI, which is integrated with a rapidly expanding database of more than 13 billion target-ligand binding interactions and supported by the company’s highly automated laboratory infrastructure.
Terray’s EMMI platform combines high-throughput chemical experimentation with generative AI-driven analysis to identify and optimize molecules for challenging drug targets, including those with no available chemical starting points. The platform uses iterative cycles of experimentation and computation, supported by a large library of quantitative structure–activity data, to accelerate discovery.
“Our AI-driven platform discovers and optimizes novel molecules for the difficult-to-drug targets—the ones with no chemistry starting point,” said Jacob Berlin, CEO of Terray Therapeutics. “We are excited about our success together and look forward to further progressing our discovery efforts.”
Terray and Bristol Myers Squibb are working together to advance small-molecule drug discovery by combining Terray’s experimental-AI integration with BMS’s therapeutic development expertise. The collaboration aims to accelerate identification of new therapies in areas with significant unmet medical need through rapid, iterative experimentation supported by advanced hardware, AI models and scientific insight.
